Mission Pharmacal Header

Mission Pharmacal Header

X

Find Novel Nephrology Drugs in Discovery

Filters

×

FILTER:

filter

Company

filter

Sponsor

filter

Country

filter

Product Type

filter

News Type

Active Filter(s):

Filters

Reset Filter

All Developments

Product Type

Companies

[{"company":"Novome Biotechnologies","sponsor":"DCVC Bio","pharmaFlowCategory":"D","amount":"$33.0 million","upfrontCash":"Undisclosed","newsHeadline":"Novome Biotechnologies Raises $33 Million Series A Financing and Appoints Blake Wise as Chief Executive Officer","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Large molecule","productStatus":"Undisclosed","date":"January 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Novome Biotechnologies"},{"company":"Walden Biosciences","sponsor":"ARCH Venture Partners","pharmaFlowCategory":"D","amount":"$51.0 million","upfrontCash":"Undisclosed","newsHeadline":"Walden Biosciences Launches to Transform the Treatment of Kidney Disease","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Discovery","country":"U.S.A","productType":"Undisclosed","productStatus":"Undisclosed","date":"October 2020","url1":"","url2":"","graph1":"Undisclosed","graph2":"Walden Biosciences"},{"company":"Kyowa Kirin","sponsor":"Harvard University","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Harvard University and Kyowa Kirin Enter Strategic Research Alliance","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Discovery","country":"JAPAN","productType":"Undisclosed","productStatus":"Undisclosed","date":"February 2021","url1":"","url2":"","graph1":"Undisclosed","graph2":"Kyowa Kirin"},{"company":"Evotec","sponsor":"Eli Lilly","pharmaFlowCategory":"D","amount":"$1,000.0 million","upfrontCash":"Undisclosed","newsHeadline":"Evotec and Lilly Enter Into Drug Discovery Collaboration in Metabolic Diseases","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Discovery","country":"GERMANY","productType":"Undisclosed","productStatus":"Undisclosed","date":"January 2022","url1":"","url2":"","graph1":"Undisclosed","graph2":"Evotec"}]

Evotec

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Evotec and Lilly Enter Into Drug Discovery Collaboration in Metabolic Diseases

Details:

The collaboration leverages Evotec’s extensive experience and track record of delivering in the field of metabolic diseases, as well as its unique and extensive kidney disease patient database, to identify and validate promising novel targets for therapeutic intervention.

Lead Product(s): Undisclosed

Therapeutic Area: Nephrology Product Name: Undisclosed

Highest Development Status: Discovery Product Type: Undisclosed

Partner/Sponsor/Collaborator: Eli Lilly

Deal Size: $1,000.0 million Upfront Cash: Undisclosed

Deal Type: Collaboration January 18, 2022

ASK
US

Upload
your Pipeline Activity

Kyowa Kirin

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Harvard University and Kyowa Kirin Enter Strategic Research Alliance

Details:

The 5-year alliance, established by Harvard’s Office of Technology Development (OTD), aims to fuel scientific collaboration among academic and industry researchers to accelerate discovery and early-stage innovation in translational biomedical science.

Lead Product(s): Undisclosed

Therapeutic Area: Nephrology Product Name: Undisclosed

Highest Development Status: Discovery Product Type: Undisclosed

Partner/Sponsor/Collaborator: Harvard University

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration February 26, 2021

ASK
US

Upload
your Pipeline Activity

Walden Biosciences

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Walden Biosciences Launches to Transform the Treatment of Kidney Disease

Details:

Walden is seeking to develop breakthrough medicines that reverse the progression of both rare and common forms of kidney disease and restore renal function.

Lead Product(s): Undisclosed

Therapeutic Area: Nephrology Product Name: Undisclosed

Highest Development Status: Discovery Product Type: Undisclosed

Partner/Sponsor/Collaborator: ARCH Venture Partners

Deal Size: $51.0 million Upfront Cash: Undisclosed

Deal Type: Series A Financing October 06, 2020

ASK
US

Upload
your Pipeline Activity

Novome Biotechnologies

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Novome Biotechnologies Raises $33 Million Series A Financing and Appoints Blake Wise as Chief Executive Officer

Details:

The financing will be used to advance the company’s lead hyperoxaluria program through Phase 1 clinical proof-of-concept work, as well as to expand its (GEMMs) platform.

Lead Product(s): Undisclosed

Therapeutic Area: Nephrology Product Name: Undisclosed

Highest Development Status: Discovery Product Type: Large molecule

Partner/Sponsor/Collaborator: DCVC Bio

Deal Size: $33.0 million Upfront Cash: Undisclosed

Deal Type: Series A Financing January 07, 2020

ASK
US

Upload
your Pipeline Activity

POST ENQUIRY